MiRNA for inhibiting Rankl and application
By using miRNAs such as miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 in osteoporosis treatment, the expression of Rankl is reduced through the gene editing system, and the side effects of existing Rankl inhibitors are solved. The problem of this has achieved a significant increase in bone mass and effective treatment of osteoporosis.
Patent Information
- Application Number
- CN202411092664.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-09
- Publication Date
- 2024-11-08
AI Technical Summary
The existing Rankl inhibitors such as desulzumab have side effects and the application of small molecule RNA in osteoporosis treatment is immature, and there is a lack of effective novel targeted Rankl methods.
Develop a miRNA that inhibits Rankl, including miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93, in hepatocytes through gene editing systems such as CasRx, siRNA or CRSPR/Cas systems, Overexpression in osteocytes, BMSCs, adipocytes, etc. to reduce Rankl expression and osteoclast production.
It significantly inhibits Rankl expression and osteoclast production, increases bone mass, and provides a new, safe and effective targeted Rankl treatment plan to reduce the symptoms and side effects of osteoporosis.
Smart Images

Figure CN118910054A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to a miRNA that inhibits Rankl and its application. Background Art
[0002] Osteoporosis (OP) is a bone metabolic disease characterized by decreased bone mass, destruction of bone microstructure, and increased bone fragility. Patients usually experience symptoms such as generalized bone pain, bone deformities, muscle weakness, and easy fractures, which seriously affect their physical and mental health and quality of life. The study of its pathogenesis and prevention and treatment strategies has important scientific significance and clinical application value. At present, the treatment of osteoporosis is mainly based on bone formation-promoting or anti-bone resorption drugs, but traditional drugs can only delay the progression of osteoporosis and cannot improve the patient's bone loss phenomenon. They can also cause toxic side effects such as jaw osteonecrosis, thromboembolism, and stroke.
[0003] The maintenance of human bone mass is mainly mediated by the dynamic balance of osteoblast activity and osteoclast activity, among which osteoclast activity is mainly regulated by the Rankl-Rank signaling axis. As the main factor in osteoclast activation, Rankl is the main target molecule for regulating bone mass by inhibiting osteoclasts. Previous studies have shown that targeting Rankl can be used as an important treatment for OP.
[0004] Previously, Rankl neutralizing antibodies such as Denosumab were used to effectively inhibit the level and activity of Rankl in the body through in vivo injection, ultimately inhibiting osteoclast activity and increasing bone mass. However, studies have shown that Denosumab has side effects such as hypocalcemia, osteonecrosis of the jaw, nausea, headache, gastrointestinal reactions, and other consequences such as rapid bone loss after discontinuation of the drug. Therefore, the development of new Rankl inhibition strategies or programs and the design of better targeted Rankl methods have important application value for the treatment of OP.
[0005] The existing technologies for the treatment of Rankl and Rankl binding processes are still immature, drugs targeting small molecule RNA are still in the early stages, and related research on small molecule RNA in the treatment of OP is also very lacking.
[0006] Therefore, there is an urgent need to explore the research on the regulation and treatment of OA development by small molecule RNA drugs, which still needs to be further improved. Summary of the invention
[0007] In view of the deficiencies in the prior art, the present invention proposes a miRNA that inhibits Rank1 and its application, providing a new, safe and effective targeted miRNA molecule for the treatment of osteoporosis.
[0008] The technical solution of the present invention is achieved in this way:
[0009] In one aspect, the present invention provides a miRNA that inhibits Rank1, wherein the miRNA is selected from miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93;
[0010] Among them, the sequence of the miR-17 is shown as SEQ ID NO·1, the sequence of the miR-20a is shown as SEQ ID NO·2, the sequence of the miR-20b is shown as SEQ ID NO·3, the sequence of the miR-106a is shown as SEQ ID NO·4, the sequence of the miR-106b is shown as SEQ ID NO·5, and the sequence of the miR-93 is shown as SEQ ID NO·6.
[0011] On the basis of this technical solution, it is further preferred that overexpression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can significantly reduce Rankl expression.
[0012] On the basis of this technical solution, it is further preferred that overexpression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can significantly inhibit osteoclastogenesis.
[0013] On the basis of this technical solution, it is further preferred that the miRNA is overexpressed in hepatocytes, bone cells, BMSCs, adipocytes or spleen cells to reduce the level of Rank1.
[0014] On the basis of this technical solution, it is further preferred that the gene editing system of the miRNA includes a CasRx system, a siRNA system or a CRSPR / Cas system.
[0015] On the basis of this technical solution, it is further preferred that the CasRx system includes Cas13 protein.
[0016] In a second aspect, the present invention further provides the use of the miRNA that inhibits Rank1 described in the first aspect in the preparation of a drug for treating osteoporosis.
[0017] On the basis of this technical solution, it is further preferred that the drug for treating osteoporosis is a drug for inhibiting osteoclast formation.
[0018] On the basis of this technical solution, it is further preferred that the drug for treating osteoporosis comprises molecules designed based on genes and proteins expressed by miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93.
[0019] In a third aspect, the present invention further provides the use of the miRNA that inhibits Rank1 as described in the first aspect as an inhibitor of osteoclast activity.
[0020] On the basis of this technical solution, it is further preferred that the osteoclast activity inhibitor is manifested as overexpression of the miRNA in hepatocytes, osteocytes, BMSCs, adipocytes, spleen cells or the digestive tract, thereby targeting the regulation of Rank1 and increasing the bone mass level.
[0021] The present invention has the following beneficial effects compared with the prior art:
[0022] The present invention shows that Rank1 in hepatocytes can mediate bone loss, so targeting hepatocyte Rank1 can be used as a therapeutic approach to treat OP.
[0023] At the same time, the present invention discovered a new Rankl interfering RNA, namely miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93. According to the targeting relationship between the above miRNA and Rankl, Rankl can be inhibited not only in the liver, but also in tissues such as bone cells, BMSCs, adipocytes, spleen cells or digestive tract, and finally the effect of significantly improving the bone mass level is achieved, indicating that overexpression of the above miRNAs can effectively inhibit Rankl and achieve the purpose of increasing bone mass, thereby providing a new and effective means for the small molecule treatment of OP. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0025] Figure 1 This is a graph showing changes in LPS and bone mass levels in liver cells with Rank1 knocked out in Application Example 1 of the present invention;
[0026] Figure 2 This is a graph showing changes in OVX and bone mass levels in hepatocytes with Rank1 knockout in Application Example 1 of the present invention;
[0027] Figure 3This is a graph showing changes in age and bone mass level in hepatocytes after Rank1 knockout in Application Example 1 of the present invention;
[0028] Figure 4 This is a graph showing changes in bone mass after editing of Rank1 mRNA in hepatocytes in Application Example 2 of the present invention;
[0029] Figure 5 This is a graph showing the expression of miR17, 20a, 20b, 106a, 106b, and 93 proteins and changes in bone mass after editing of Rank1 mRNA in hepatocytes in Application Example 2 of the present invention. DETAILED DESCRIPTION
[0030] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0031] Based on the expression level of Rank1, the present invention found that the expression of Rank1 in the liver can effectively mediate LPS, OVX and senile OP, and the decrease in bone mass caused by the above factors can be effectively prevented by knocking out Rank1 in the liver. In addition, based on the gene and mRNA sequence of Rank1, several miRNAs that can target Rank1 were found, and overexpression of the above miRNAs can effectively inhibit the expression of Rank1. Overexpression of miRNA in the liver can effectively increase bone mass. In addition, the present invention uses mRNA editing technology to knock down Rank1 in the liver, and found that it can effectively reduce osteoclast activity and increase bone mass in mice, confirming that miRNA and liver Rank1 can be used as a new type of target molecule for the treatment of OP.
[0032] Example 1
[0033] This embodiment provides a miRNA that inhibits Rank1, wherein the miRNA is selected from miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93;
[0034] Specifically, in a preferred embodiment, as shown in Table 1, Table 1 is the primer sequence of the miRNA, and it can be seen that the sequence of the miR-17 is shown in SEQ ID NO. 1, the sequence of the miR-20a is shown in SEQ ID NO. 2, the sequence of the miR-20b is shown in SEQ ID NO. 3, the sequence of the miR-106a is shown in SEQ ID NO. 4, the sequence of the miR-106b is shown in SEQ ID NO. 5, and the sequence of the miR-93 is shown in SEQ ID NO. 6. In the nucleotide sequence table, in order to comply with the WIPOST.26 standard, all "U"s are replaced with "T" to ensure the validity of the sequence, and the actual sequence is subject to Table 1; in RNA, uracil (U) is the counterpart of thymine (T).
[0035] Table 1 Primer sequences of miRNA
[0036]
[0037] Specifically, in a preferred embodiment, overexpression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can significantly reduce Rank1 expression.
[0038] Specifically, in a preferred embodiment, overexpression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can significantly inhibit osteoclastogenesis.
[0039] Specifically, in a preferred embodiment, the miRNA is overexpressed in hepatocytes, bone cells, BMSCs, adipocytes or spleen cells to reduce the level of Rank1.
[0040] Specifically, in a preferred embodiment, the miRNA gene editing system includes a CasRx system, a siRNA system or a CRSPR / Cas system.
[0041] Specifically, in a preferred embodiment, the CasRx system includes Cas13 protein.
[0042] In the present invention: 6-8 week old C57BL / 6 female mice were purchased from a certain experimental animal company, and all mouse experiments were carried out according to the animal experiment protocol approved by a certain experimental animal center.
[0043] Specifically, in a preferred embodiment, the application examples also provide the use of miRNA as an inhibitor of osteoclast activity.
[0044] Specifically, in a preferred embodiment, the osteoclast activity inhibitor is manifested as overexpression of the miRNA in hepatocytes, osteocytes, BMSCs, adipocytes, spleen cells or the digestive tract, thereby targeting the regulation of Rank1 and increasing bone mass levels.
[0045] Osteoclast induction differentiation experiment, the specific steps are as follows:
[0046] 1. RAW264.7 cells (American Type Culture Collection, ATCC) were cultured and expanded in modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS).
[0047] 2. Induce differentiation of RAW264.7 cells into osteoclasts: Culture in an induction medium containing RANKL (50 ng / ml) for 2 days to obtain TRAP-positive osteoclast precursor cells (preOC), and continue to culture for 4 days to obtain multinucleated mature osteoclasts (mOC). Change the medium every 2 days.
[0048] 3. The cells were stained with a tartrate-resistant acid phosphatase staining kit (Sigma). TRAP-positive multinucleated cells were mature osteoclasts.
[0049] Quantitative analysis of mature miRNA, the specific steps are as follows:
[0050] 1. Design reverse transcription primers and quantitative PCR primers based on mature miRNA sequences, as shown in Table 1.
[0051] 2. Dilute the primers with water to a final concentration of 1 μM.
[0052] 3. Reverse transcription reaction.
[0053] The specific steps of drug screening experiment are as follows:
[0054] Mouse osteoblasts, which can endogenously express miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93, are used as a cell model for screening drugs for preventing, alleviating or treating OP.
[0055] Test group: cultures of the above cells treated with the candidate substance;
[0056] Control group: the culture of the above cells not treated with the candidate substance, ie, the Ctrl group in the figure.
[0057] At an appropriate time after treatment, the cells are assayed for expression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93.
[0058] If the expression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 in the test group is significantly increased by 50% or more compared to the control group, it indicates that the candidate substance is a potential substance for preventing, alleviating or treating OP. The above cells are transfected with miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 as candidate substances.
[0059] The results showed that Trap staining showed a significant decrease in osteoclast activity, and therefore, miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can be used as candidate drugs for useful osteoclast activity inhibitors.
[0060] Application Example 1
[0061] A method for knocking out Rankl in liver cells, the specific steps are as follows:
[0062] Rankl was knocked out in mouse hepatocytes using the Cre-Loxp system. In 2-month-old mice, lipopolysaccharide (LPS) was injected into the mice (20 mg / kg). After 7 days, the mouse samples were collected and the femoral bone mass and spine bone mass were analyzed using microCT. Cell source: RAW264.7 mouse mononuclear macrophage leukemia cells were purchased from a cell bank of a certain academy of sciences.
[0063] Cell culture: RAW264.7 cells with good growth status were selected and cultured at 2×10 4 The cells were seeded at a density of / well in a 24-well plate and incubated in a 37°C, 5% CO2 incubator.
[0064] Cell transfection: After the cells were stably cultured for 4-6 hours, Rankl-miRNA or control miRNA was added to the cells according to the instructions of RNAiMAX Transfection Reagent. The supernatant was discarded 48 hours after transfection, and RNA and protein samples were collected to detect the expression of Rankl gene and protein.
[0065] q-PCR detection of gene silencing effect
[0066] (1) RNA extraction: RNA was extracted according to the instructions of the Promega RNA extraction kit.
[0067] (2) RNA reverse transcription to cDNA synthesis According to the reverse transcription instructions of Takara's kit, total RNA was reverse transcribed into cDNA. The reaction conditions are as follows: 37°C, 15 min; 85°C, 5 s; 4°C, ∞.
[0068] (3) Real-time PCR (qRT-PCR) The qRT-PCR reaction solution was prepared on ice using the Real-time PCR kit provided by Promega according to the instructions. The specific formula is shown in Table 3. After the reaction solution was prepared, the qRT-PCR amplification program was set as follows: 95°C, 30 s; 95°C, 5 s; 60°C, 34 s; 45 cycles, and then tested on the machine.
[0069] The experimental results used Rank1 as the internal reference gene, the negative control group samples as calibration samples, and different stimulation groups as test samples. The 2-ΔΔCt method was used to calculate and compare the expression changes of the target gene.
[0070] Western Blot detection of protein silencing effect
[0071] (1) Extraction of total protein
[0072] 1. Discard the cell culture supernatant and wash the 6-well plate cells twice with pre-cooled PBS. Add the newly prepared lysis buffer RIPA100 to the wells and let it stand for 10 minutes. Then use a scraper to scrape the attached cells at the bottom of the 6-well plate.
[0073] 2. Use a 200° pipette to suck up the scraped cell solution (be careful to blow it up and down) and transfer it into a 1.5 ml EP tube and put it back on ice. Vortex once every 5 minutes for a total of 3 times.
[0074] 3. Centrifuge at 4°C, 12000g for 15 min.
[0075] (2) Protein quantification: perform protein quantification according to the instructions of the BCA protein quantification kit. Boil in a metal bath at 100°C for 5 min to denature the protein.
[0076] (3) SDS-PAGE electrophoresis
[0077] 1. Prepare gel: Prepare separation gel and stacking gel according to Table 5, and then add protein sample (30 μg / lane). Perform electrophoresis at 80V for 15min for stacking gel and 120V for 80min for separation gel.
[0078] 2. Transfer: Lay the membrane in the following order: (bottom) black laminating clamp → black sponge → white filter paper → glue → PVDF membrane (marked) → white filter paper → black sponge → transparent laminating clamp (top). After the PVDF membrane and glue are clamped, transfer the membrane at 100V constant voltage for 90 minutes.
[0079] 3. Blocking: Pour 5% skim milk prepared with TBST into the blocking box and block at room temperature for 1 hour.
[0080] 4. Primary antibody incubation: After blocking, roll the cut membrane into the corresponding Rankl and β-actin primary antibodies and incubate overnight at 4°C.
[0081] 5. Wash the membrane and incubate with secondary antibody: Wash the membrane with TBST solution the next day, once every 10 minutes, for a total of 3 times. After washing, incubate with secondary antibody for 1 hour. Wash the membrane with TBST solution, once every 5 minutes, for a total of 6 times.
[0082] 6. Exposure and development: Cover the prepared ECL luminescent liquid on the surface of the PVDF membrane, shake it slightly left and right to evenly distribute the ECL luminescent liquid, incubate it in the dark for 2 minutes, and place it in the instrument for imaging.
[0083] 7. Grayscale analysis: Use ImageJ software to perform optical density analysis on the target band and the internal reference band.
[0084] The results show that if Figure 1 As shown, Figure 1 This is a graph showing changes in LPS and bone mass levels in hepatocytes with Rank1 knockout in this example. Figure 1 AC in Figure 2 represent the femoral bone mass and LPS level in mice lacking liver Rankl. Figure 1 D and E in the figure represent the LPS levels in the spine of mice lacking liver Rankl. Figure 1 F in the figure is a representative picture of osteoclast activity shown by Trap staining of bone sections, which indicates that the absence of Rankl in mouse liver can cause mice to resist LPS-induced bone loss. Specifically, there was no difference in bone mass between the non-injected mice. After LPS injection, the bone mass of the control group mice decreased significantly, and the degree of bone mass decrease in the knockout group mice was much lower than that in the control group.
[0085] Since estrogen deficiency can lead to decreased bone mass in mice, we aimed to confirm whether the decreased bone mass caused by estrogen deficiency affects Rankl deficiency in hepatocytes.
[0086] Specifically, in a preferred embodiment, this application example studies whether the bone mass loss caused by estrogen deficiency can be resisted by hepatocyte Rankl deficiency. The mouse ovarian removal (OVX) model is used to simulate the osteoporosis caused by estrogen deficiency in humans. Two months after OVX surgery, the bone mass of mice was detected by microCT.
[0087] The results show that Figure 2 As shown, Figure 2 AC in the figure represents the femoral bone mass and OVX level of mice lacking liver Rankl, where Sham is the sham model group, that is, the animals were opened in the abdomen for modeling, while the sham group only underwent opening in the abdomen and no other treatment was performed. Figure 2 D and E in the figure represent the levels of OVX in the spine of mice lacking liver Rankl. Figure 2F in the figure is a representative picture of osteoclast activity shown by Trap staining of bone sections. When mice underwent OVX surgery and Rankl in the liver was knocked out at the same time, the mice were significantly protected from the decrease in bone mass induced by OVX, which indicates that targeting Rankl in hepatic cells can protect against osteoporosis caused by estrogen deficiency.
[0088] In addition to inflammation and estrogen deficiency, the causes of osteoporosis also include aging and other factors, among which aging is one of the most important factors.
[0089] Furthermore, in order to clarify whether targeting liver cells Rankl can be used for OP caused by aging.
[0090] Specifically, in a preferred embodiment, mice of different ages were examined using microCT, and their bone mass changes were determined.
[0091] The results show that Figure 3 As shown, Figure 3 AC in the figure represents the femoral bone mass and age level of mice lacking liver Rankl. Figure 3 D and E in the figure represent the spinal bone mass levels of mice lacking liver Rankl. Figure 3 F in the figure is a representative picture of osteoclast activity shown by Trap staining of bone sections. With age, the difference in bone mass between the knockout group and the control group increased significantly, which was age-dependent. Correspondingly, the difference in osteoclast activity shown by Trap staining also increased significantly. The above results show that targeting hepatocyte Rankl can effectively protect OP caused by aging.
[0092] Application Example 2
[0093] Using CasRx (Cas13)-mediated mRNA gene editing, different sgRNAs were designed, plasmids were constructed, and 48 hours after transfection into bone cells, the expression level of the Rank1 target gene was detected by PCR and WB. After comparing different sgRNAs, the optimal sgRNA was obtained for in vivo application research in mice.
[0094] Table 2 Primer sequences of sgRNA
[0095]
[0096] Table 2 shows the primer sequences of sgRNA in Application 2. It can be seen that the sequence of Rank1-sg1 is shown in SEQ ID NO·7, the sequence of Rank1-sg2 is shown in SEQ ID NO·8, the sequence of Rank1-sg3 is shown in SEQ ID NO·9, the sequence of Rank1-sg4 is shown in SEQ ID NO·10, and the sequence of Rank1-sg5 is shown in SEQ ID NO·11.
[0097] like Figure 4 As shown, Figure 4 AC in the figure represents the femoral bone mass and age level of mice lacking liver Rankl. Figure 4 D and E in the figure represent the spinal bone mass levels of mice lacking liver Rankl. Figure 4 F in the figure is a representative picture of osteoclast activity shown by Trap staining of bone sections.
[0098] The results showed that mRNA gene editing-mediated Rankl liver knockdown can effectively increase the bone mass of mice. MicroCT detection showed a significant increase in bone mass in mice, while Trap staining showed a significant decrease in osteoclast activity. Figure 4 This confirms that the knockdown strategy can also significantly increase bone mass in mice.
[0099] Application Example 3
[0100] By analyzing the Rankl sequence, a group of miRNAs, namely miR17, 20a, 20b, 106a, 106b, and 93, were found to target Rankl mRNA. In vitro experiments showed that overexpression of the above miRNAs could effectively inhibit the expression level of Rankl. Therefore, the above miRNAs can inhibit osteoclast activity and increase bone mass by inhibiting the expression level of Rankl. To verify this conclusion, miR17-20a was overexpressed using an overexpression system.
[0101] The results show that if Figure 5 As shown, Figure 5 AD in the figure indicates the expression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 protein in the femur of mice lacking liver Rankl, indicating that miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 directly targets Rankl and regulates the mRNA level to ultimately affect protein expression. Among them, GAPDH is the internal reference protein of Western Blot. Figure 5 EG in the figure indicates femoral bone mass after hepatocytes overexpress miR17-20a. Figure 5 H and I in the figure are the spinal bone mass of mice. Figure 5 J in the figure is a representative picture of osteoclast activity shown by Trap staining of bone sections.
[0102] Overexpression of miR17-20a can effectively increase the bone mass of mice and weaken osteoclast activity. The above results show that overexpression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can inhibit osteoclast activity by inhibiting Rankl, and different strategies of overexpressing miR17, 20a, 20b, 106a, 106b, 93 can be used as an osteoclast activity inhibitor for the treatment of OP.
[0103] In summary, the present invention provides a miRNA for inhibiting Rankl and its application. A new miRNA, namely miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93, can inhibit Rankl not only in the liver, but also in tissues such as bone cells, BMSCs, adipocytes, spleen cells or digestive tract, and can be used as a targeting molecule in the treatment of OP or osteoclast activity inhibitors, and can play a good inhibitory effect.
[0104] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A miRNA that inhibits Rank1, characterized in that The miRNA is selected from miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93; Among them, the sequence of the miR-17 is shown as SEQ ID NO·1, the sequence of the miR-20a is shown as SEQ ID NO·2, the sequence of the miR-20b is shown as SEQ ID NO·3, the sequence of the miR-106a is shown as SEQ ID NO·4, the sequence of the miR-106b is shown as SEQ ID NO·5, and the sequence of the miR-93 is shown as SEQ ID NO·6.
2. The miRNA that inhibits Rank1 according to claim 1, characterized in that Overexpression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can significantly reduce Rank1 expression.
3. The miRNA that inhibits Rank1 according to claim 1, characterized in that Overexpression of miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93 can significantly inhibit osteoclastogenesis.
4. The miRNA that inhibits Rank1 according to claim 1, characterized in that The miRNA is overexpressed in hepatocytes, bone cells, BMSCs, adipocytes or spleen cells to reduce the level of Rank1.
5. Use of the miRNA that inhibits Rank1 as described in any one of claims 1 to 4 in the preparation of a drug for treating osteoporosis.
6. The use according to claim 5, characterized in that The drug for treating osteoporosis is a drug for inhibiting the formation of osteoclasts.
7. The use according to claim 6, characterized in that The osteoporosis treatment drug prepared includes molecules designed based on genes and proteins expressed by miR-17, miR-20a, miR-20b, miR-106a, miR-106b or miR-93.
8. Use of the miRNA that inhibits Rank1 as claimed in any one of claims 1 to 4 as an inhibitor of osteoclast activity.
9. The use according to claim 8, characterized in that The osteoclast activity inhibitor is manifested as the overexpression of the miRNA in hepatocytes, osteocytes, BMSCs, adipocytes or spleen cells, which targets and regulates Rank1 and increases the bone mass level.
